Gene Therapy for Keratin Genodermatoses: Striving Forward but Obstacles Persist  by Bowden, Paul E.
commentary
 www.jidonline.org 1403
(Moss et al., 1995) led to the conclusion 
that the mutant protein’s dominant neg-
ative effect could be diluted, obviating 
the need to remove the mutant protein 
completely, in order to obtain a normal 
phenotype.
Although the majority of keratin 
mutations are dominant negative, a small 
number of recessively inherited muta-
tions have been identified in patients 
with epidermolysis bullosa simplex (EBS) 
(Chan et al., 1994; Rugg et al., 1994; 
Jonkman et al., 1996; Landschuetzer 
et al., 2003). These are generally null 
mutations, in which there is no prod-
uct from the defective gene; thus, they 
are silent in the heterozygous state. It is 
interesting that only K14-null mutations 
have been reported, and the absence of 
K5 (polymerization partner of K14) has 
never been identified. This implies that 
K5-null epidermal stem cells cannot 
survive (embryo lethal). Nonsense and 
some frameshift mutations can intro-
duce premature termination codons in 
the N-terminal portion of such proteins, 
and the resulting unstable mRNA is then 
removed as a consequence of triggering 
nonsense-mediated decay (Chang et al., 
2007). This effectively silences the gene 
and leads to an absence of protein from 
the mutant allele. In a heterozygous 
setting this would be clinically unre-
markable, but in a homozygous state a 
disease phenotype will result because of 
the total absence of protein. Interestingly, 
nonsense-mediated decay has also been 
observed in patients with recessive forms 
of epidermolytic hyperkeratosis caused 
by homozygous KRT10 nonsense muta-
tions (Terheyden et al., 2009).
are null-state mutations less disruptive 
than dominant negative mutations?
Null mutations cause a functional 
absence of one member of a keratin 
pair. Although this weakens the IF net-
work within the cell, it is thought to 
be less disruptive than the continued 
presence of mutant keratin protein 
aggregates. Research presented by 
D’Alessandro et al. (2011, this issue) 
and in other publications (Batta et al., 
2000; Landschuetzer et al., 2003) sug-
gests that null mutations cause a milder 
phenotype. This reasoning is based 
on the observation that aggregates of 
misfolded keratin protein activate a 
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Keratin genodermatoses:  
a dominant negative theme
A link between keratin defects and 
a group of genetic skin fragility dis-
orders became apparent in the early 
1990s. Research into the function of 
the intermediate filament (IF) network 
in cells indicated that disruption to the 
C-terminal portion of a keratin mono-
mer would collapse the IF network, sig-
nificantly weaken the cell, and lead to 
skin disease in mice (Vassar et al., 1991). 
IF collapse occurred in both cultured 
cells and transgenic mice, even though 
mutant proteins comprised only 50% of 
the specific keratin involved and this rep-
resented only 25% of the total keratin in 
the filament (obligatory hetero polymers 
require two different keratin subunits, a 
product of four alleles). This dominant 
negative effect was thought to pose 
an impenetrable barrier to successful 
gene therapy because the mutant pro-
tein would need to be removed before 
any introduced wild-type protein could 
have a corrective effect. However, later 
evidence from studies of patients with 
phenotypic and genotypic mosaicism 
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stress kinase cascade that contributes 
to disease pathology and worsens phe-
notype. Thus, cells containing domi-
nant negative mutations are thought to 
be stress sensitive, whereas cells with 
null mutations are thought to be able 
to resist stress activation, resulting in a 
milder phenotype (D’Alessandro et al., 
2002; Russell et al., 2010). This logic 
is supported by the observation that 
heat shock gave rise to keratin aggre-
gates only in cells carrying a dominant 
negative mutation (and not in K14-null 
cells).
However, different causes of null 
mutations can produce phenotypes 
of variable severity (Chan et al., 1994; 
Batta et al., 2000). It has been known 
for some time that disease severity 
in patients bearing keratin mutations 
depends somewhat on the position of 
the mutation (Letai et al., 1993) and the 
actual change (e.g., amino acid substi-
tution, insertion, deletion, splice defect) 
that occurs. Variability is apparent in 
D’Alessandro and colleagues’ study, in 
which the K14-null status resulted from 
two different mutations (in two dif-
ferent families) (see Rugg et al., 1994, 
and Jonkman et al., 1996). The result-
ing K14-null cell lines behaved dif-
ferently in migration assays: KEB-11 
responded in a manner similar to that 
of normal NEB-1 cells, whereas KEB-13 
responded in a manner similar to that of 
KEB-7 (a dominant negative cell line). 
However, altered migration was nor-
malized in both cell lines by the addi-
tion of wild-type K14. Also, whereas 
K14-null cells were clearly stressed, the 
levels of JNK phosphorylation detect-
ed were not as high as those observed 
for dominant negative mutations (e.g., 
KEB-7); again, the addition of wild-type 
K14 reduced these levels to normal.
The question of compensatory 
expression of other keratins in a null 
situation is also a matter of some 
debate. In the absence of K14, it 
has always been assumed that other 
type I keratins are overexpressed and 
copolymerize with the unpaired K5. 
However, although the K14-null cells 
can be clearly shown to have an IF net-
work, identification of the type I part-
ner is more of a challenge. Although 
D’Alessandro et al. demonstrated that 
K14-null cells expressed K17, K18, 
and K19, little change in expression 
levels was observed compared with 
normal keratinocytes, and the copoly-
merizing keratin in the K14-null cells 
was not identified. However, earlier 
studies of K14-null mutations impli-
cated a limited compensatory role for 
K15 (Jonkman et al., 1996).
Genotype–phenotype relationships: 
understanding the effect of  
keratin mutations
Thus, in keratin genodermatoses, the 
relationship between a mutated gene 
and the resulting altered cutaneous cel-
lular pathology in a specific patient can 
be complex. Even within a family, the 
same mutation can produce different 
phenotypes. In EBS, some mutations in 
the early 1A helical region (p.N176S 
and p.F179S in K5, for example) 
caused a severe phenotype (Stephens 
et al., 1997), but a similar mutation 
between these two codons (p.N177S in 
K5) produced a mild phenotype (Liovic 
et al., 2004). Thus, it is not only the 
gross location of the mutation but also 
the functional effect of altering specif-
ic codons that influences phenotype. 
The genetic background of an individ-
ual also plays an important role in the 
effect of a given mutation, and there 
has been much discussion concern-
ing the role of modifier genes. Thus, if 
genes can be identified that ameliorate 
the pathophysiology that results from 
disease-causing mutations, then over-
expression of such genes may prove 
beneficial in terms of therapy.
Natural reversion is a rare event, 
but there have been reports of a 
few instances. Partial reversion was 
observed in a patient with recessive EBS 
caused by a homozygous K14 splice 
mutation and leading to an absence 
of viable transcripts (Schuilenga-Hut 
et al., 2002). However, skin biopsy 
revealed mosaic expression of K14 in 
basal epidermal cells, and further inves-
tigation revealed an additional K14 
transcript that was able to reconstitute 
the IF network. The phenotype was not 
improved because this new transcript 
was also abnormal but not susceptible 
to nonsense-mediated decay.
More recently, mitotic recombina-
tion has been shown to cause rever-
sion of a dominant negative mutation 
in KRT10, resulting in a phenotype 
termed ichthyosis with confetti (also 
known as congenital reticular ichthyosi-
form erythroderma). A group of muta-
tions in the intron 6–exon 7 boundary 
region of KRT10 results in a frameshift 
that creates an arginine-rich C-terminal 
peptide in K10. This altered K10 protein 
is sequestered from the IF network into 
the nucleolus, causing cellular fragility, 
altered differentiation, and parakerato-
sis. However, patients with ichthyosis 
with confetti exhibit extensive somatic 
loss of heterozygosity of the mutant 
locus on chromosome 17; this gener-
ates islands of normal skin attributable 
to positive selective pressure on stem 
cells with a wild-type profile present-
ing as white areas on a red background 
(Choate et al., 2010).
Epidermolytic hyperkeratosis (EHK) 
also exists as a mosaic, a condition 
called linear epidermal nevus, in which 
clones of normal cells are interspersed 
with mutant cells. Causal mutations 
have been identified in KRT10 (Moss et 
al., 1995), but the main point of interest 
is that normal skin adjacent to the nevi 
has a mixture of normal and mutant 
cells, with normal cells predominant. 
This implies that complete correction 
of dominant negative keratin mutations 
Clinical Implications
•  K14-null cells provide a model system for studying gene therapy for 
cutaneous genodermatoses.
•  Stress responses to mutant proteins form an important part of the 
phenotype observed in dominant negative keratin disorders, and 
blocking these responses may be of therapeutic value.
•  Currently, siRNA technology offers the best gene therapy for autosomal 
dominant inherited skin disease.
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may not be necessary to provide a rea-
sonable clinical outcome. This was 
further supported by work with mouse 
models of EHK and EBS, in which selec-
tive pressure on stem cells explained 
why mosaic forms of EHK persist 
whereas EBS mosaics have not been 
observed (Arin and Roop, 2004).
approaches to corrective gene therapy 
for keratin disorders
The majority of keratin genodermatoses 
exhibit autosomal dominant inheri-
tance, and the mutant protein exerts a 
dominant negative effect over the nor-
mal protein. Treatment would require 
a different approach from that used for 
the rarer autosomal recessive keratin 
disorders, where replacement of a sin-
gle copy functional gene might be suf-
ficient to rescue the phenotype (Long 
et al., 2009).
Currently, research is aimed at 
removing the product of a mutant allele 
by targeting the mRNA carrying the 
mutation. This requires high specific-
ity because in the majority of patients 
only a single base change is involved. 
Early attempts were made by design-
ing ribozymes, but more specific tar-
geting has been possible using small 
interfering RNA (siRNA) silencing 
technology (Lewin et al., 2005). Recent 
work on pachyonychia congenita type 
1 (PC1), caused by dominant negative 
mutations in KRT6A (or KRT16), has 
indicated that siRNA knockdown suffi-
cient to correct the phenotype can be 
achieved in cultured cells and in mouse 
models (Leachman et al., 2008). This 
technology is currently being evaluated 
in phase I clinical trials as a means of 
treating patients with PC1.
Another route for cutaneous gene 
therapy is to correct stem cells in an ex 
vivo setting and then to apply the cor-
rected cells to the patient’s skin. It has 
been shown in mouse models that cor-
rected stem cells can repopulate stem 
cell niches in the skin (Arin and Roop, 
2004). However, these cells are correct-
ed using adenovirus or lentivirus vectors, 
and they can be susceptible to reversion 
over time (Lewin et al., 2005). There can 
also be significant hurdles to reapplying 
cells to the skin of patients because the 
presence of any viral DNA sequences 
may trigger an immune response.
A third route to correcting cutane-
ous genodermatoses would be to leave 
the defective gene in place and tackle 
the factors that cause the phenotype. 
Augmentation of wild-type keratins or 
their paralogs (such as K15 induction to 
supplement loss of K14) might be able 
to stabilize the IF network even in the 
presence of mutant protein. Blocking 
the cellular stress response to protein 
aggregates may prevent the cell from 
entering a self-destructive cycle.
concluding remarks
D’Alessandro and colleagues have 
demonstrated that K14-null cells 
can be rescued by the addition of 
wild-type protein and that the stress 
responses associated with keratin dis-
orders can be ameliorated. More work 
is needed on cells that contain mutant 
keratin proteins to assess whether 
replacing wild-type protein can over-
come the dominant negative effect of 
the mutation or whether the only way 
forward in the majority of keratin dis-
orders is to silence the mutant protein. 
Furthermore, although correction in 
cultured cells and in mouse models 
is an important prerequisite for gene 
therapy approaches in patients, obsta-
cles still exist in terms of successful 
corrective gene therapy in vivo.
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